Skip to main content
Top
Published in: BMC Public Health 1/2013

Open Access 01-12-2013 | Research article

Prevalence and epidemiological correlates and treatment outcome of HCV infection in an Italian prison setting

Authors: Micaela Brandolini, Stefano Novati, Annalisa De Silvestri, Carmine Tinelli, Savino Francesco Antonio Patruno, Roberto Ranieri, Elena Seminari

Published in: BMC Public Health | Issue 1/2013

Login to get access

Abstract

Background

The aim of the present study is to test in the feasibility of a screening programme for HCV infection in an Italian prison and to evaluate the treatment outcomes.

Method

Single-centre cross-sectional study carried out in Milan-Opera. The HCV infection prevalence was calculated on the imprisoned population on the January 31 2006, the data on treatment over the following 2 years. Treatment option offered to HCV chronically infected patients was then analysed, reasons for not being treated was evaluated.

Results

Of the 965 inmates, 695 were enrolled in the study, 682 (98%) were males, the median age was 43 years. There were 131 (18.8%) foreigners and 564 (81.2%) Italians. HCV seroprevalence was 22.4%(95% CI:19.4%-25.7%), 60 subjects (38.4%) being HIV co-infected too. Prevalence of HCV infection was significantly higher in HIVAb positive (89.6%; 95% CI:79.7%-95.7%) than in HIVAb negative (15.15%; 95% CI 12.6%-18.3%) (p<0.001). Among Italian inmates HCVAb positivity was significantly higher than among foreigners (p=0.0154). Among HCVAb positive patients, 135 subjects were HCV-RNA positive. Forty-seven (36%) had major clinical contraindication to treatment, 18 (13%) refused the treatment, 7 (5%) moved to other Institute and 27 (20%) were not evaluated by infectious disease specialists. Fifteen patients (43%) who received treatment were considered responders, 9 (26%) were non responders/relapsers, 6 (17%) interrupted treatment due to side effects and 5 (14%) were released during treatment and lost in follow-up.

Conclusions

This study indicates that the proportion of patients in a prison setting receiving diagnosis and treatment for HCV infection remained low.
Appendix
Available only for authorised users
Literature
1.
go back to reference Spaulding AC, Weinbaum CM, Lau DT, Sterling R, Seeff LB, Margolis HS, Hoofnagle JH: A framework for management of hepatitis C in prisons. Ann Intern Med. 2006, 144 (10): 762-769. 10.7326/0003-4819-144-10-200605160-00010.CrossRefPubMed Spaulding AC, Weinbaum CM, Lau DT, Sterling R, Seeff LB, Margolis HS, Hoofnagle JH: A framework for management of hepatitis C in prisons. Ann Intern Med. 2006, 144 (10): 762-769. 10.7326/0003-4819-144-10-200605160-00010.CrossRefPubMed
2.
go back to reference Saiz De La Hoya P, Marco A, García-Guerrero J, Rivera A: Hepatitis C and B prevalence in Spanish prisons. Eur J Clin Microbiol Infect Dis. 2011, 30 (7): 857-862. 10.1007/s10096-011-1166-5.CrossRefPubMed Saiz De La Hoya P, Marco A, García-Guerrero J, Rivera A: Hepatitis C and B prevalence in Spanish prisons. Eur J Clin Microbiol Infect Dis. 2011, 30 (7): 857-862. 10.1007/s10096-011-1166-5.CrossRefPubMed
3.
go back to reference Babudieri S, Longo B, Sarmati L, Starnini G, Dori L, Suligoi B, Carbonara S, Monarca R, Quercia G, Florenzano G, Novati S, Sardu A, Iovinella V, Casti A, Romano A, Uccella I, Maida I, Brunetti B, Mura MS, Andreoni M, Rezza G: Correlates of HIV, HBV, and HCV infections in a prison inmate population: results from a multicentre study in Italy. J Med Virol. 2005, 76 (3): 311-317. 10.1002/jmv.20375.CrossRefPubMed Babudieri S, Longo B, Sarmati L, Starnini G, Dori L, Suligoi B, Carbonara S, Monarca R, Quercia G, Florenzano G, Novati S, Sardu A, Iovinella V, Casti A, Romano A, Uccella I, Maida I, Brunetti B, Mura MS, Andreoni M, Rezza G: Correlates of HIV, HBV, and HCV infections in a prison inmate population: results from a multicentre study in Italy. J Med Virol. 2005, 76 (3): 311-317. 10.1002/jmv.20375.CrossRefPubMed
4.
go back to reference Sabbatani S, Giuliani R, Fulgaro C, Paolillo P, Baldi E, Chiodo F: HIVAb, HCVAb and HBsAg seroprevalence among inmates of the prison of Bologna and the effetct of counselling on the compliance of proposed tests. Epidemiol Prev. 2004, 28 (3): 163-168.PubMed Sabbatani S, Giuliani R, Fulgaro C, Paolillo P, Baldi E, Chiodo F: HIVAb, HCVAb and HBsAg seroprevalence among inmates of the prison of Bologna and the effetct of counselling on the compliance of proposed tests. Epidemiol Prev. 2004, 28 (3): 163-168.PubMed
6.
go back to reference Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD: Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003, 138 (3): 187-190. 10.7326/0003-4819-138-3-200302040-00010.CrossRefPubMed Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD: Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003, 138 (3): 187-190. 10.7326/0003-4819-138-3-200302040-00010.CrossRefPubMed
7.
go back to reference Maru DS, Bruce RD, Basu S, Altice FL: Clinical outcomes of hepatitis C treatment in a prison setting: feseability and effectiveness for challenging treatment populations. CID. 2008, 47: 952-961. 10.1086/591707.CrossRef Maru DS, Bruce RD, Basu S, Altice FL: Clinical outcomes of hepatitis C treatment in a prison setting: feseability and effectiveness for challenging treatment populations. CID. 2008, 47: 952-961. 10.1086/591707.CrossRef
8.
go back to reference Marco A, Esteban JI, Solé C, da Silva A, Ortiz J, Roget M, Sarriera C, Teixidó N, Guerrero RA, Caylà JA: Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. J Hepatol. 2013, in press Marco A, Esteban JI, Solé C, da Silva A, Ortiz J, Roget M, Sarriera C, Teixidó N, Guerrero RA, Caylà JA: Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. J Hepatol. 2013, in press
9.
go back to reference Sabbatani S, Giuliani R, Manfredi R: Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting. Braz J Infect Dis. 2006, 10 (4): 274-278. 10.1590/S1413-86702006000400012.CrossRefPubMed Sabbatani S, Giuliani R, Manfredi R: Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting. Braz J Infect Dis. 2006, 10 (4): 274-278. 10.1590/S1413-86702006000400012.CrossRefPubMed
12.
go back to reference Weinbaum C, Lyerla R, Margolis HS, Centers for Disease Control and Prevention: Prevention and control of infections with hepatitis viruses in correctional settings. MMWR Recomm Rep. 2003, 52 (RR-1): 1-36.PubMed Weinbaum C, Lyerla R, Margolis HS, Centers for Disease Control and Prevention: Prevention and control of infections with hepatitis viruses in correctional settings. MMWR Recomm Rep. 2003, 52 (RR-1): 1-36.PubMed
13.
go back to reference Vescio MF, Longo B, Babudieri S, Starnini G, Carbonara S, Rezza G, Monarca R: Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. J Epidemiol Community Health. 2008, 62: 305-313. 10.1136/jech.2006.051599.CrossRefPubMed Vescio MF, Longo B, Babudieri S, Starnini G, Carbonara S, Rezza G, Monarca R: Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. J Epidemiol Community Health. 2008, 62: 305-313. 10.1136/jech.2006.051599.CrossRefPubMed
14.
go back to reference Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, Hagan H, Rich JD, van den Bergh BJ, Degenhardt L: The incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology. 2013, in press Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, Hagan H, Rich JD, van den Bergh BJ, Degenhardt L: The incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology. 2013, in press
15.
go back to reference Rantala M, van de Laar MJ: Surveillance and epidemiology of hepatitis B and C in Europe - a review. Euro Surveill. 2008, 13: 21- Rantala M, van de Laar MJ: Surveillance and epidemiology of hepatitis B and C in Europe - a review. Euro Surveill. 2008, 13: 21-
16.
go back to reference Colbert AM, Sekula LK, Zoucha R, Cohen SM: Health care needs of women immediately post-incarceration: a mixed methods study. Public Health Nurs. 2013, 30 (5): 409-419. 10.1111/phn.12034.CrossRefPubMed Colbert AM, Sekula LK, Zoucha R, Cohen SM: Health care needs of women immediately post-incarceration: a mixed methods study. Public Health Nurs. 2013, 30 (5): 409-419. 10.1111/phn.12034.CrossRefPubMed
17.
go back to reference Ford N, Kirby C, Singh K, Mills EJ, Cooke G, Kamarulzaman A, duCros P: Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis. Bull World Health Organ. 2012, 90 (7): 540-550.CrossRefPubMedPubMedCentral Ford N, Kirby C, Singh K, Mills EJ, Cooke G, Kamarulzaman A, duCros P: Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis. Bull World Health Organ. 2012, 90 (7): 540-550.CrossRefPubMedPubMedCentral
18.
go back to reference van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL: Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012, 308 (24): 2584-2593. 10.1001/jama.2012.144878.CrossRefPubMed van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL: Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012, 308 (24): 2584-2593. 10.1001/jama.2012.144878.CrossRefPubMed
19.
go back to reference Baillargeon J, Soloway RD, Paar D, Giordano TP, Murray O, Grady J, Williams B, Pulvino J, Raimer BG: End-stage liver disease in a state prison population. Ann Epidemiol. 2007, 17 (10): 808-813. 10.1016/j.annepidem.2007.04.005.CrossRefPubMed Baillargeon J, Soloway RD, Paar D, Giordano TP, Murray O, Grady J, Williams B, Pulvino J, Raimer BG: End-stage liver disease in a state prison population. Ann Epidemiol. 2007, 17 (10): 808-813. 10.1016/j.annepidem.2007.04.005.CrossRefPubMed
20.
go back to reference Sherman KE, O’Brien J, Gutierrez AG, Harrison S, Urdea M, Neuwald P, Wilber J: Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infection. J Clin Microbiol. 1993, 31: 2679-2682.PubMedPubMedCentral Sherman KE, O’Brien J, Gutierrez AG, Harrison S, Urdea M, Neuwald P, Wilber J: Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infection. J Clin Microbiol. 1993, 31: 2679-2682.PubMedPubMedCentral
21.
go back to reference Martín-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, Arizcorreta A, Gonzalez A, Rockstroh J, Asensi V, Miralles P, Laguno M, Moreno L, Girón JA, Vogel M, García-Samaniego J, Nuñez M, Romero M, Moreno S, de la Cruz JJ, Soriano V: Incidence and predictors of severe liver fibrosis in HIV infected patients with chronic hepatitis C: European Collaborative Study. Clin Infect Dis. 2004, 38: 128-133. 10.1086/380130.CrossRefPubMed Martín-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, Arizcorreta A, Gonzalez A, Rockstroh J, Asensi V, Miralles P, Laguno M, Moreno L, Girón JA, Vogel M, García-Samaniego J, Nuñez M, Romero M, Moreno S, de la Cruz JJ, Soriano V: Incidence and predictors of severe liver fibrosis in HIV infected patients with chronic hepatitis C: European Collaborative Study. Clin Infect Dis. 2004, 38: 128-133. 10.1086/380130.CrossRefPubMed
22.
go back to reference Seminari E, Tinelli C, Ravasi G, Ripamonti D, Ladisa N, Marino N, Sighinolfi L, Mondello P, Migliorino M, Carosi G, Maserati R: Hepatitis C infection on immune recovery in HIV-positive patients on successful HAART: the role of genotype 3. Curr HIV Res. 2010, 8 (3): 186-193. 10.2174/157016210791111070.CrossRefPubMed Seminari E, Tinelli C, Ravasi G, Ripamonti D, Ladisa N, Marino N, Sighinolfi L, Mondello P, Migliorino M, Carosi G, Maserati R: Hepatitis C infection on immune recovery in HIV-positive patients on successful HAART: the role of genotype 3. Curr HIV Res. 2010, 8 (3): 186-193. 10.2174/157016210791111070.CrossRefPubMed
23.
go back to reference Baillargeon JG, Paar DP, Wu H, Giordano TP, Murray O, Raimer BG, Avery EN, Diamond PM, Pulvino JS: Psychiatric disorders, HIV infection and HIV/hepatitis co-infection in the correctional setting. AIDS Care. 2008, 20 (1): 124-129. 10.1080/09540120701426532.CrossRefPubMed Baillargeon JG, Paar DP, Wu H, Giordano TP, Murray O, Raimer BG, Avery EN, Diamond PM, Pulvino JS: Psychiatric disorders, HIV infection and HIV/hepatitis co-infection in the correctional setting. AIDS Care. 2008, 20 (1): 124-129. 10.1080/09540120701426532.CrossRefPubMed
24.
go back to reference Farley J, Vasdev S, Fischer B, Haydon E, Rehm J, Farley TA: Feasibility and outcome of HCV treatment in a Canadian federal prison population. Am J Public Health. 2005, 95 (10): 1737-1739. 10.2105/AJPH.2004.056150.CrossRefPubMedPubMedCentral Farley J, Vasdev S, Fischer B, Haydon E, Rehm J, Farley TA: Feasibility and outcome of HCV treatment in a Canadian federal prison population. Am J Public Health. 2005, 95 (10): 1737-1739. 10.2105/AJPH.2004.056150.CrossRefPubMedPubMedCentral
Metadata
Title
Prevalence and epidemiological correlates and treatment outcome of HCV infection in an Italian prison setting
Authors
Micaela Brandolini
Stefano Novati
Annalisa De Silvestri
Carmine Tinelli
Savino Francesco Antonio Patruno
Roberto Ranieri
Elena Seminari
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2013
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-13-981

Other articles of this Issue 1/2013

BMC Public Health 1/2013 Go to the issue